12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Crush-resistant Opana ER oxymorphone regulatory update

FDA issued a complete response letter for an NDA from Endo for a crush-resistant formulation of Opana ER oxymorphone to treat moderate to severe pain in patients...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >